NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis $85.26 -0.01 (-0.01%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$85.50 +0.24 (+0.28%) As of 05:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About GeneDx Stock (NASDAQ:WGS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GeneDx alerts:Sign Up Key Stats Today's Range$84.36▼$87.6250-Day Range$59.10▼$90.2952-Week Range$32.21▼$170.87Volume331,595 shsAverage Volume450,421 shsMarket Capitalization$2.54 billionP/E RatioN/ADividend YieldN/APrice Target$89.57Consensus RatingModerate Buy Company Overview GeneDx Holdings Corp., doing business as GeneDx, is a healthcare company focused on genetic testing and genomic diagnostics. The company provides testing designed to help healthcare professionals diagnose rare and inherited conditions, guide clinical management, and support research into genetic disease. Its offerings include whole exome and whole genome sequencing, targeted genetic tests, chromosomal microarray analysis, and other tests used to identify disease-causing genetic variants. GeneDx also provides variant interpretation, genetic data analysis, and related services for physicians, hospitals, researchers, biopharmaceutical companies, and other healthcare organizations. GeneDx was founded in 2000 and became part of Sema4 in 2022 after being acquired from OPKO Health. Sema4 subsequently adopted the GeneDx name, and the company trades on the Nasdaq under the symbol WGS. GeneDx serves customers in the United States and internationally and is led by Chief Executive Officer Katherine Stueland.AI Generated. May Contain Errors. Read More GeneDx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreWGS MarketRank™: GeneDx scored higher than 39% of companies evaluated by MarketBeat, and ranked 719th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingModerate Buy Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for GeneDx is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageGeneDx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GeneDx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GeneDx are expected to grow in the coming year, from ($0.41) to $1.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is -23.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is -23.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 8.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeneDx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.89% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 12.43, which indicates bearish sentiment.Change versus previous monthShort interest in GeneDx has recently decreased by 4.58%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.90 News SentimentGeneDx has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for GeneDx this week, compared to 8 articles on an average week.Search Interest9 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows1 people have added GeneDx to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,283,920.00 in company stock.Percentage Held by Insiders25.17% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WGS Stock News HeadlinesInsider Selling: GeneDx (NASDAQ:WGS) CEO Sells $310,940.24 in Stock1 hour ago | americanbankingnews.comGeneDx (NASDAQ:WGS) CFO Kevin Feeley Sells 1,285 Shares of StockSeptember 12 at 6:52 AM | insidertrades.comElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company the same size Nvidia was a decade ago. Brown says this firm's patented technology can produce intelligence up to 1,000 times faster than standard AI, and he expects Elon Musk to fuel demand starting November 11. The technology is protected by 150 patents.September 14 at 1:00 AM | Brownstone Research (Ad)GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells InvestorsAugust 26, 2026 | gurufocus.comGeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’sAugust 24, 2026 | uk.finance.yahoo.comGeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children'sAugust 24, 2026 | markets.ft.comGeneDx: Why I Think The Worst Is Behind The BusinessAugust 18, 2026 | seekingalpha.comGeneDx (WGS) Q2 2026 Earnings Call TranscriptAugust 12, 2026 | finance.yahoo.comSee More Headlines WGS Stock Analysis - Frequently Asked Questions How have WGS shares performed this year? GeneDx's stock was trading at $130.06 at the beginning of the year. Since then, WGS stock has decreased by 34.4% and is now trading at $85.26. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) announced its quarterly earnings data on Monday, August, 3rd. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.20. The company earned $114.44 million during the quarter, compared to analysts' expectations of $111.01 million. GeneDx had a positive trailing twelve-month return on equity of 4.12% and a negative net margin of 23.41%. Read the conference call transcript. When did GeneDx's stock split? Shares of GeneDx reverse split on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GeneDx's major shareholders? Top institutional shareholders of GeneDx include California State Teachers Retirement System (5.05%), First Light Asset Management LLC (2.63%), Wellington Management Group LLP (1.17%) and Assenagon Asset Management S.A. (1.02%). Insiders that own company stock include Keith A Meister, Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Katherine Stueland, Kevin Feeley, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Joshua Ruch, Jason Ryan and Bryan Dechairo. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeneDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings8/03/2026Today9/13/2026Next Earnings (Estimated)10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 WGS's financial health is in the Green zone, according to TradeSmith. WGS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:WGS CIK1818331 Webwww.genedx.com Phone800-298-6470FaxN/AEmployees1,300Year Founded2000Price Target and Rating Average Price Target for GeneDx$89.57 High Price Target$150.00 Low Price Target$63.00 Potential Upside/Downside+5.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.02 million Net Margins-23.41% Pretax Margin-23.39% Return on Equity4.12% Return on Assets2.26% Debt Debt-to-Equity Ratio0.40 Current Ratio3.30 Quick Ratio3.06 Sales & Book Value Annual Sales$427.54 million Price / Sales5.95 Cash Flow$2.29 per share Price / Cash Flow37.20 Book Value$10.54 per share Price / Book8.09Miscellaneous Outstanding Shares29,820,000Free Float22,317,000Market Cap$2.54 billion OptionableOptionable Beta1.99 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:WGS) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
